Showing 11,881 - 11,900 results of 85,538 for search '(( 50 ((we decrease) OR (((a decrease) OR (mean decrease)))) ) OR ( 2 c decrease ))', query time: 1.90s Refine Results
  1. 11881
  2. 11882

    NADPH oxidation and H<sub>2</sub>O<sub>2</sub> production by Bs3 and Bs3<sub>S211A</sub>. by Christina Krönauer (11301989)

    Published 2021
    “…<p>A) Buffer containing 100 μM NADPH was mixed with 0.2 μM Bs3 or Bs3<sub>S211A</sub> and incubated at 25°C. …”
  3. 11883
  4. 11884
  5. 11885

    Effects of Cyr61 and Wnt5a on regenerating vasculature and musculature. by Devon C. Snow-Lisy (798898)

    Published 2015
    “…At both 4 and 10 weeks, Cyr61KD demonstrated significantly decreased vasculature as compared to Cyr61OX. Data shown as means ± SEM; ***P<0.001 for Cyr61KD vs Cyr61OX. …”
  6. 11886
  7. 11887
  8. 11888

    Increased expression of AQP4 protein after hypoglycemia/recovery and decreased expression of tight junction proteins. by Jiangshan Deng (636062)

    Published 2014
    “…C. Representative picture revealed the decrease of ZO-1 after hypoglycemia. …”
  9. 11889
  10. 11890
  11. 11891
  12. 11892
  13. 11893
  14. 11894
  15. 11895
  16. 11896
  17. 11897

    Ophthalmic administration of CXCR3 antagonist decreases intraocular pressure in a rat model of ocular hypertension. by Alexandre Denoyer (160189)

    Published 2012
    “…<i>(B)</i> When the antagonist is administrated twice, intraocular pressure remains low during 6 weeks (n = 10 each); the black arrow indicates the period of retinal and visual <i>in vivo</i> testing presented in <i>Fig. 6A,B</i>. <i>(C)</i> Dose-dependent effect of two administrations of CXCR3 antagonist on intraocular pressure as tested two weeks after the treatment (n = 5 each). * <i>P</i><0.05, ** <i>P</i><0.01. …”
  18. 11898
  19. 11899
  20. 11900